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Interleukin-15 (IL-15) is a cytokine which inhibits lipid deposition in cultured adipocytes and decreases adipose tissue deposition
in laboratory rodents. In human subjects, negative correlations between circulating IL-15 levels and both total and abdominal
fat have been demonstrated. Deletions of IL15 in humans and mice are associated with obesity, while gain-of-function IL-15
overexpressing mice are resistant to diet-induced obesity. IL-15 is highly (but not exclusively) expressed at the mRNA level in
skeletal muscle tissue, and the regulation of IL-15 translation and secretion is complex. Conﬂicting evidence exists concerning
whether circulating IL-15 is released from skeletal muscle tissue in response to exercise or other physiological stimuli. The IL-15
receptor-alpha (IL-15Rα) subunit has a complex biochemistry, encoding both membrane-bound and soluble forms which can
modulate IL-15 secretion and bioactivity. The gene encoding this receptor, IL15RA, resides on human chromosome 10p, a location
linked to obesity and type-2 diabetes. Several single-nucleotide polymorphisms (SNPs) in human IL15RA and IL15 correlate with
adiposity and markers of the metabolic syndrome. Genetic variation in IL15RA may modulate IL-15 bioavailability, which in
turn regulates adiposity. Thus, IL-15 and the IL-15Rα may be novel targets for pharmacologic control of obesity in the human
population.
1.Introduction
The increased incidence of obesity in both developed and
developing nations is a major public health problem [1].
Altered energy balance resulting in obesity is believed to
be causal in the development of the metabolic syndrome
and type-2 diabetes mellitus, conditions whose incidence is
also rising at alarming rates [2, 3]. The economic burden
of obesity and diabetes in the U.S. is currently in excess of
$200 billion annually, and it is expected to rise [1]. Diet
and lifestyle modiﬁcations are often unsuccessful in reduc-
ing obesity [4–6], and presently available pharmacologic
treatments are problematic due to serious adverse eﬀects
[7]. Therefore, research involving novel pathways to control
adiposity is warranted.
Here, evidence that interleukin-15 (IL-15) can inhibit
adipose tissue deposition in both laboratory animals and
human subjects will be reviewed. Additionally, the complex
regulation of IL-15 expression and secretion will be summa-
rized. The speciﬁc receptor for IL-15, IL-15 receptor-alpha
(IL-15Rα), appears to regulate IL-15 secretion, stability,
and activity [8, 9]. Several single-nucleotide polymorphisms
(SNPs) in human IL15 and IL15RA have been described
which correlate with adiposity and markers of the metabolic
syndrome [10–12]. These ﬁndings suggest a model in which
genetic variation in IL15RA could modulate IL-15 activity
and bioavailability, which in turn regulate adiposity. More-
over, because IL-15 mRNA is highly expressed in skeletal
muscle tissue, some authors have suggested that IL-15 may
function as a muscle-derived endocrine factor, or “myokine”,
which can modulate body composition [13–16]. Evidence in
support of, and against, this hypothesis will be discussed.
When human genetic, cell culture, and laboratory animal
studies are taken together, it is clear that the IL-15/IL-15Rα2 Journal of Obesity
axis regulates adiposity. Modulation of this axis should be
explored a novel target for control of obesity in the human
population.
2. Molecular GeneticsandExpressionof
IL-15 withRegard to Adipose Tissue
IL-15 is a 14kDa cytokine that was originally isolated
on the basis of its ability to support natural killer (NK)
T-lymphocyte proliferation [17]. IL-15 was subsequently
f o u n dt ob ee x p r e s s e db ym o n o c y t e s ,m a c r o p h a g e s ,a n d
other cell types involved in immunity and to regulate a
variety of processes comprising both innate and adaptive
immunity reviewed in [18]. IL-15 exhibits both pro- and
anti-inﬂammatory actions in a variety of tissues and has
both positive anticancer eﬀects via stimulation of NK cells,
and deleterious eﬀects such as involvement in inﬂammatory
boweldisease(reviewedin[18,19]).Inasmuchasthepresent
paper is focused on the relationship of IL-15 to obesity, the
reader is referred to comprehensive reviews of the diverse
functions of IL-15 provided by Fehniger and Caligiuri [18]
and Budagian et al. [19].
IL-15 is structurally part of the 4-helix bundle protein
family [17], whose members exhibit structural, but not
necessarily sequence, homology [20]. This family of proteins
includes many cytokines which regulate the immune system
and also includes factors with actions outside of the immune
system, such as IL-6, leptin, growth hormone, and erythro-
poietin[20].IL-15isexpressedatthemRNAlevelinavariety
of nonlymphoid tissues, with particularly high expression
in skeletal muscle and placenta [17]. IL-15 is also expressed
abundantly in cardiac muscle, lung, liver, kidney, brain, and
pancreas [17]. In the placenta, IL-15 regulates a speciﬁc
subset of NK cells involved in endometrial decidualization
[21].
In nonlymphoid tissues, IL-15 has been implicated in
processes ranging from angiogenesis [22] to skeletal muscle
hypertrophy [23].Conﬂictingreports[14,24]existregarding
IL-15 mRNA expression in cultured adipocytes (reviewed
below), and a systematic study of IL-15 expression in adipose
tissue in vivo has not been conducted. Both humans and
laboratory mice exhibit detectable levels of IL-15 in the
circulation, (for example, [9, 10, 15, 25]), allowing for
the possibility that IL-15 can exert endocrine (as well as
paracrine) eﬀects on cell types which do not express IL-
15 itself. However, the tissues from which circulating IL-15
originates are unknown. Because of the high expression of
IL-15 in skeletal muscle and evidence that other cytokines
such as IL-6 are released from muscle following physical
activity, some investigators have suggested IL-15 functions as
a myokine which exerts positive eﬀects on body composition
via an endocrine mechanism [13–16]. Conﬂicting evidence
for IL-15 as a myokine is reviewed below.
As mentioned above, another tissue which exhibits high
expression of both IL-15 mRNA and protein is placenta [17,
26, 27]. In a study comparing concentrations of numerous
cytokines in amniotic ﬂuid and sera of normal pregnant
women, Chow et al. [27] reported signiﬁcantly higher IL-15
concentrations in serum than in amniotic ﬂuid, consistent
with literature indicating many cytokines do not cross
the placental barrier. However, studies of whether gravid
animals or pregnant women display increased circulating
levels of IL-15 compared to nongravid or nonpregnant
females are lacking. In any case, such an observation would
not apply to males and does not preclude skeletal muscle
or other tissues as additional sources of IL-15 in both
genders.
Two IL-15 mRNA isoforms are generated from a single
IL15 gene in humans and mice [28, 29]. The two isoforms
diﬀer in the lengths of the signal peptides and have been
designatedlongsignalpeptide(LSP)andshortsignalpeptide
(SSP)-IL-15 mRNA [28]. However, tissue expression and
intracellular traﬃcking of these isoforms are dissimilar [28,
29]. SSP-IL-15 mRNA is highly transcribed in heart, and
also expressed in thymus, testes, and appendix, whereas LSP-
IL-15 mRNA is transcribed strongly in skeletal muscle and
placenta, and at lower levels in heart, lung, liver, thymus,
and kidney [28]. SSP-IL-15 does not appear to be secreted,
and either functions intracellularly or is released following
cell damage [28, 29]. LSP-IL-15 is secreted; however, the
unusually long 48 amino acid signal peptide renders IL-
15 secretion extremely ineﬃcient [28–31]. IL-15 protein
expression is also regulated at the translational level [31–33].
LSP-IL-15 protein translation is impeded by multiple AUGs
(initiation codons) in the 5  untranslated region [31–33].
BecauseoftheineﬃciencyofIL-15 translation andsecretion,
correlations between IL-15 mRNA levels and secretion of
IL-15 protein are often weak (reviewed in [18, 33]). A
systematic comparison of IL-15 protein expression among
tissues has not been conducted, and it is technically diﬃcult
to demonstrate secretion from a speciﬁc tissue in vivo,
particularly in mouse models.
Conﬂicting reports exist as to whether IL-15 is expressed
by adipocytes. The mouse 3T3-L1 adipogenic cell line does
not express levels of IL-15 mRNA detectable by highly
sensitive real-time PCR at any stage of diﬀerentiation [14].
However,anotherstudydemonstratedprimarypigadipocyte
cultures express IL-15 mRNA at low basal levels, which are
upregulated following stimulation with interferon-γ [24].
Whether IL-15 protein was produced or released into the
culture medium was not determined. Diﬀerences between
rodents and swine, and/or between adipogenic cell lines and
primary cultures, as well as between adipocytes in vivo and
in vitro, are quite possible.
In obesity, adipose tissue develops an inﬂammatory
environment due to inﬁltrating macrophages which are a
source of numerous proinﬂammatory cytokines [34, 35].
In a mouse strain highly susceptible to oxidative stress,
high dietary calcium in conjunction with an obesigenic
diet signiﬁcantly stimulated IL-15 mRNA expression in
both visceral fat and skeletal muscle tissue [36], but it
was not determined which cell types were responsible for
the upregulated IL-15 message. A systematic study of IL-
15 mRNA and protein expression in various depots of fat
tissue, in diﬀerent physiological conditions, has not been
performed. Thus, whether adipocytes and/or adipose tissue
can express and secrete IL-15 protein in basal conditions orJournal of Obesity 3
in inﬂammatory challenges associated with obesity remains
unclear.
3. Effects of Interleukin-15onAdipose Tissue
The IL-15 gene (IL15; human accession number U14407)
is mapped to human chromosome 4q31 and the central
regionofchromosome8inmice[37].Arecentgenome-wide
survey of human copy number variations which correlated
with obesity revealed a large (2.1Mb) deletion of a region
which included both IL15 and the gene encoding the
mitochondrial uncoupling protein UCP1 [38]. Since the role
of UCP1 in modulating energy balance is well described
[39], the potential contribution of loss of IL15 by this large
deletion was not additionally considered. However, research
ﬁndings from adipogenic cell cultures, laboratory animals,
and human subjects all suggest IL-15 may also function as an
antiobesigenic factor.
In a study of human subjects comprising a wide range
of body mass indices (BMI), Nielsen et al. [15]f o u n d
negative associations between plasma IL-15 concentrations
and BMI (P<. 001), total fat mass (P<. 001), trunk fat
mass (P<. 01), and limb fat mass (P<. 05). Negative
associations between muscle IL-15 mRNA and obesity
parameters were also observed in that study [15]. A similar
ﬁnding was reported by Barra et al. [40] who observed obese
human subjects exhibited lower circulating IL-15 levels than
lean subjects. However, Christiansen et al. [41]r e p o r t e d
decreased circulating IL-15 concentrations following diet-
induced weight loss in obese human subjects. Two SNPs
in human IL15 (rs1589241 and rs1057972) are associated
withvariouspredictorsofthemetabolicsyndrome,BMI,and
musclestrength[10,11].TheseSNPsarelocatedinthe5  and
3  untranslated regions (UTRs) of the gene, suggesting they
could modulate IL-15 expression.
Mice with targeted deletion of IL15 (IL-15KO mice)
exhibit higher amounts of body fat than control mice
[40]. Conversely, transgenic mice which were engineered for
elevatedcirculatinglevelsofIL-15(IL-15Tgmice),expressed
from a skeletal muscle-speciﬁc promoter, exhibited lower
levels of body fat than closely related controls, and were
resistant to diet-induced obesity [42]. In the same study,
mice which expressed high intramuscular levels of IL-15 but
which did not exhibit elevated serum IL-15 levels showed no
diﬀerences in adiposity compared to controls, suggesting IL-
15 must be secreted into the circulation to exert its eﬀects
on adipose tissue [42]. Since this is an artiﬁcially constructed
system, it can model, but does not prove, the hypothesis that
muscle-derived IL-15 acts as a myokine in the native state.
IL-15 has also been introduced into wild-type laboratory
rodents by injection of recombinant IL-15 protein [13,
40], by adenoviral expression vectors [40], and by DNA
electrotransfer into skeletal muscle [15]. In these studies,
IL-15 administration reduced fat mass by as much as 30%
in normal rodents and 10% in obese rodents. Importantly,
inhibitionoffatdepositionwasobservedintheabsenceofan
eﬀectofIL-15onfoodconsumption[13,40].Additionally,in
the studies of both IL-15KO mice and the gain-of-function
IL-15 Tg mice described above [40, 42], no eﬀects of loss
or overexpression of IL-15 on food intake were observed.
Therefore, the eﬀects of IL-15 on adipose tissue are not
likely to be due to an indirect eﬀect of modiﬁed energy
intake. However, one report indicated chronic treatment of
rats with IL-15 slightly inhibited intestinal absorption of
triaclglycerols speciﬁcally [43]. Lean body mass is unaﬀected
by IL-15 [13, 40, 42], indicating IL-15 does not induce
a cachectic state; indeed, recombinant IL-15 injection can
p r e v e n tl o s so fs k e l e t a lm u s c l em a s si nr o d e n tm o d e l so f
cancer cachexia [44].
Recombinant IL-15 has been administered by injection
into rodent genetic obesity models. IL-15 injection inhibited
fat deposition in both wild-type and leptin-deﬁcient obese
(ob/ob)m i c e[ 45]. IL-15 administration to lean rats also
inhibited fat deposition, but it was unable to inhibit fat
deposition in leptin receptor-deﬁcient obese (fa/fa)Z u c k e r
rats [45]. Obese, but not lean, rats exhibited signiﬁcant
decreases in adipose tissue expression of mRNA for two
of the subunits of the heterotrimeric IL-15 receptor, the
IL-2 receptor beta and gamma subunits (IL-2Rβ and IL-
2Rγ), while expression of adipose tissue IL-15Rα mRNA
was unchanged [45]. This observation suggests that adipose
tissue of obese Zucker rats failed to respond to IL-15 because
the signaling subunits (IL-2Rβ and IL-2Rγ) of the IL-15
receptor were downregulated in adipose tissue in this strain,
and that the eﬀect of IL-15 on adipose tissue is direct.
ThedirecteﬀectofIL-15onadiposetissuewasconﬁrmed
using adipogenic cell cultures derived from several mam-
malian species, including human [14, 40, 46]. Recombinant
IL-15 administration inhibited preadipocyte diﬀerentiation
and lipid deposition in the immortalized mouse 3T3-L1
cell line [14]. Moreover, in diﬀerentiated 3T3-L1 adipocytes,
IL-15 dose-dependently stimulated secretion of the insulin-
sensitizing and antiobesigenic factor adiponectin [14]. Sim-
ilar results were observed by another laboratory using cul-
tured primary porcine adipocytes, in which IL-15 potently
stimulated lipolysis and modestly inhibited lipogenesis [46].
Finally, Barra et al. [40] found that administration of IL-15
to lipoaspirate-derived human adipocyte cultures inhibited
lipid deposition. The molecular pathways mediating the
eﬀects of IL-15 on adipose tissue have not been character-
ized in detail. One study [47] suggested IL-15 upregulates
expression of calcineurin mRNA, a factor which inhibits
adipocyte diﬀerentiation. Further work is needed to conﬁrm
and expand this observation.
4.IL-15 asaPotentialMyokine
In contrast to adipose tissue, IL-15 mRNA and protein
expression has been observed consistently in skeletal mus-
cle and skeletal muscle-derived culture systems [23, 48–
51], where it functions to modulate myoﬁbrillar protein
dynamics [23, 44]. At the protein level, IL-15 has been
immunolocalized to human skeletal muscle ﬁbers in tissue
sections which contained few IL-15-positive inﬁltrating
cells [48]. Nielsen et al. [49]d e t e c t e dI L - 1 5p r o t e i nb y
immunohistochemistry and Western blotting in human4 Journal of Obesity
skeletalmusclewithbothtype-1andtype-2ﬁberdominance,
which did not correlate with the respective levels of IL-
15 mRNA expression in these muscles. Expression of IL-
15 mRNA and biologically active IL-15 protein has been
detected in primary human myogenic cultures [48], human
rhabodomyosarcoma-derived cell lines [50], and a rat clonal
myogenic cell line [51]. IL-15 mRNA expression is low, but
detectable, in mouse C2C12 skeletal myogenic cultures at
the myoblast stage, but it is induced about 10-fold upon
diﬀerentiation [23]. Therefore, published evidence indicates
IL-15 is expressed by skeletal muscle ﬁbers themselves, not
vascular, connective tissue, or lymphoid inﬁltrating cells
present in muscle and in primary cultures. However, it
is unclear if these observations translate to meaningful
contributions to circulating IL-15 levels by skeletal muscle
tissue.
Several cytokines, most notably interleukins −6, −8, and
−10, are released from skeletal muscle following physical
activity, resulting in large changes in plasma concentrations
of such “myokines” [52, 53]. One study found that in human
skeletal muscle, IL-15 was the mostly highly expressed of
all cytokines measured at the mRNA level [52]. Since both
IL-15 and physical exercise have positive eﬀects on body
composition, it is reasonable to hypothesize IL-15 release
following exercise may mediate some of the beneﬁcial eﬀects
of physical activity [16, 54]. However, there are conﬂicting
reports as to whether physical activity aﬀects IL-15 expres-
sion in skeletal muscle and/or increases circulating IL-15
levels. In a study of young untrained and 10-week-trained
human subjects, Riechman et al. [10] demonstrated an
increaseinplasmaIL-15proteinlevelsimmediatelyfollowing
whole-body resistance exercise and speculated that IL-15 was
released following exercise via microtears in muscle ﬁbers.
However, there was no eﬀect of training on the postexercise
release of IL-15 in that study, casting doubt upon muscle
damage as the mechanism. In contrast, a similar study using
untrained human subjects reported no increase in muscle or
circulatingIL-15proteinlevelsatintervalsfrom6to48hours
following an intensive resistance exercise protocol which
involved only the quadriceps muscles; however, increases in
quadricepsmuscleIL-15mRNAexpressionwereobserved24
hoursafterexercise[49].Discrepanciesbetweenthesestudies
maybeduetothediﬀerencesintheintervalsbetweenexercise
and blood sampling.
Prior training or physical condition may modulate the
purported release of IL-15 from skeletal muscle tissue by
exercise. Using strength-trained human subjects, Nieman
et al. [53] observed no changes in muscle IL-15 mRNA
following two hours of intensive weight training. Similarly,
Ostrowski et al. [55] observed no changes in plasma IL-
15 following 2h of treadmill running by 2 male athletes,
and Andersson et al. [56] found no acute eﬀects of com-
petition on IL-15 levels in elite female soccer athletes. In
contrast, using sedentary postmenopausal women, Prestes
et al. [57] reported an increase in plasma IL-15 levels 48
hours following the ﬁrst session of resistance training but no
eﬀect following 16 weeks of training. Finally, Christiansen
et al. [41] studied chronic (not acute) plasma cytokine
levels in obese, physically inactive subjects subjected to
a program of intensive (hypocaloric) dietary intervention,
aerobic exercise, or the combination of diet and exercise.
Comparedtobaseline,dietaloneandthecombinationofdiet
and exercise signiﬁcantly decreased circulating IL-15 levels,
whereas aerobic exercise alone had no eﬀect. However, given
the extremely hypocaloric nature of the dietary intervention
(600–800kcal/day), it is possible some loss of muscle tissue
occurred, which was not examined. Beavers et al. [58]
similarly reported no eﬀect of a 12-month program of
combined aerobic, strength and balance intervention on
circulating IL-15 levels in frail elderly subjects. It is possible
that diﬀerences among these studies were due to the use
of highly trained versus untrained, obese, and/or elderly
subjects and/or to the diﬀerence between aerobic versus
resistance exercise. Therefore, evidence for the hypothesis
that IL-15 is released following exercise is mixed and largely
negative. Moreover, an increase in circulating IL-15 levels
after exercise is only circumstantial evidence of its derivation
from skeletal muscle tissue. For example, although skeletal
muscle expresses the myostatin-inhibiting factor follistatin, a
recent study provided evidence that the postexercise rise in
circulating follistatin is mostly likely derived from the liver
rather than from muscle tissue [59].
The concept of IL-15 as a “myokine” does not necessarily
imply that it is released by exercise, rather it implies simply
that the factor is derived from skeletal muscle tissue and is
released in quantities suﬃcient to have an endocrine eﬀect
on other cell types. Such release also does not necessarily
imply that expression of the purported myokine is speciﬁc
to skeletal muscle tissue. On the other hand, skeletal muscle
tissue comprises almost 50% of body mass and is specialized
for protein synthesis, if not secretion, so a small release
of a bioactive factor from each muscle could have a large
systemic eﬀect. Sporadic reports of other inﬂammatory,
hormonal, or nutritional factors which aﬀect muscle IL-15
mRNA expression and circulating IL-15 protein levels have
beenpublished. Using elderlyhuman malesubjects,Lambert
et al. [60] administered the synthetic progestin megestrol
acetate at 800mg/d for 12wk, with or without testosterone
(100mg/wk), resistance training, or the combination of
resistance training and testosterone. Progestin ingestion, but
no other treatment, caused highly signiﬁcant increases in
circulating IL-15 levels, but this treatment did not correlate
w i t hc h a n g e si nm u s c l em a s so rb o d yc o m p o s i t i o n .A s
mentioned above, dietary calcium signiﬁcantly stimulated
IL-15 mRNA expression in murine skeletal muscle tissue
(as well as visceral fat) in obesigenic conditions and oxida-
tive stress, which was interpreted as an increase in anti-
inﬂammatory cytokine expression due to calcium-mediated
inhibition of 1,25-dihydroxyvitamin D3 [36]. In myogenic
cell cultures, overexpression of an orphan nuclear hormone
receptor which is highly expressed in muscle, retinoid-
related orphan receptor gamma, upregulated both IL-15 and
myogenin mRNA, as well as expression of several genes
which regulate lipid and carbohydrate metabolism, insulin
sensitivity, and reactive oxygen species [61]. Cultured rat
myocytes upregulated IL-15 mRNA in response to both the
inﬂammatory factor interferon-γ and the anti-inﬂammatory
cytokine IL-4 [51], while primary human myoblast culturesJournal of Obesity 5
increased expression of both intracellular and secreted IL-
15 protein in response to several inﬂammatory mediators
(interferon-γ, interleukin-1α, interleukin-1β,T N F - α,a n d
lipopolysaccharide) [48]. These observations suggest muscle
IL-15 expression is modulated by dietary, hormonal, and
inﬂammatory status, but, as in the experiments dealing with
exercise, a clear understanding of the regulation of IL-15
expression by such factors in skeletal muscle tissue is lacking.
Increased age is an important predictor of obesity and
the metabolic syndrome [3, 62]. Reports in animal models
on the eﬀects of age on IL-15 expression in muscle and in
serum are conﬂicting. Pistilli et al. [63] found that IL-15
mRNA was elevated in both slow and fast aging rat muscles
compared to young muscles. The same study found that IL-
15 mRNA was elevated in atrophied slow soleus muscles of
young rats but not in the fast plantaris muscle. A similar
eﬀect of aging and immobilization recovery on IL-15 mRNA
in rat muscles was reported in another study [64]. However,
given the complex regulation of IL-15 described above, it is
unclear whether these changes in IL-15 mRNA expression
reﬂect similar changes in muscle IL-15 protein expression
and secretion in these physiological states. Indeed, in mice,
both muscle and serum IL-15 protein levels were reported
to decline progressively with increasing age; however, this
decline was not accompanied by decreases in transcription
of either SSP- or LSP-IL-15 mRNA [25]. Rather, while
expression of the membrane-associated form of IL-15Rα
(mbIL-15Rα) did not change with age, an age-related decline
in expression of muscle soluble IL-15Rα (sIL-15Rα)m R N A
inmuscletissuewasdemonstrated[25],suggestingdecreased
expression of this factor (reviewed below) could lead to age-
related declines in IL-15 secretion from muscle. In another
study [65], a similar decline in muscle IL-15 protein levels
(and muscle IL-15Rα mRNA expression) in ad lib-fed rats
was described, but no declines in IL-15 protein levels or
IL-15Rα mRNA expression were observed in long-lived,
calorie-restricted rats [65]. Intriguingly, Gangemi et al. [66]
observed that while serum IL-15 concentrations exhibited
a downward trend with age in unselected human subjects,
individuals with unusually long lifespans (95 to more than
100 years) and still living independently had signiﬁcantly
elevated circulating IL-15 levels, suggesting elevated IL-
15 levels conferred some protection against age-related
illness.
5.The Soluble IL-15 Receptor-Alpha as
a Modulator of IL-15 Secretion
IL-15 signaling is transduced either through a heterodimeric
receptor comprising IL-2Rβ and IL-2Rγ, or through a
heterotrimeric receptor comprising mbIL-15Rα plus IL-2Rβ
and IL-2Rγ [67]. The IL-2Rβ and IL-2Rγ subunits are
responsible for signal transduction, while mbIL-15Rα has
only a short cytoplasmic region and functions primarily to
confer high-aﬃnity binding to the receptor complex [67].
Cells can express heterodimeric and heterotrimeric IL-15
receptor complexes simultaneously or express IL-15Rα in
the absence of the other two subunits [67]. Adipose tissue
expresses all three IL-15 receptor subunits at the mRNA level
[45].
Unexpectedly, mice in which the IL-15Rα is deleted
(IL15RαKO mice) are leaner, rather than fatter, than controls
[68]. This observation suggests a complex role for this
receptorsubunitincontrolofbody fat,andisconsistentwith
the idea that the IL-15Rα can function in roles other than a
membrane-bound receptor component.
The molecular genetics of IL-15Rα are complex. IL15RA
(human accession number U31628) is located on mouse
chromosome 2 and human chromosome 10p [69]. Loci
on human chromosome 10p have been strongly linked to
both obesity and type-2 diabetes [70, 71]. Human and
mouse IL15RA exhibit similar genomic structures ([67,
69] and reviewed in [19]). IL15RA has an eﬃcient signal
sequence (exon 1), a ligand-binding domain (exon 2), a
transmembrane domain (exon 6), and, as mentioned, a
fairly short cytoplasmic domain (exon 7). Exon 2 encodes
a conserved protein-binding region known as a “sushi”
domain, which is responsible for the binding aﬃnity of IL-
15Rα for the IL-15 ligand [67, 69]. A number of IL-15Rα
mRNA splice variants have been reported in both mouse
and human, some of which encode soluble forms which may
modulate IL-15 secretion and bioavailability [19]. Because
both isoforms of IL-15 have ineﬃcient signal sequences,
recent experimental evidence suggests IL-15 is brought to
the cell surface by intracellular association with either sIL-
15Rα or mbIL-15Rα, both of which would include the
eﬃcient exon-1-encoded IL-15Rα signal sequence [8]. Two
forms of sIL-15Rα have been characterized. One, which
arises by diﬀerential splicing, comprises only exons 1 and
2, so does not contain a transmembrane domain [9]. IL-15
secretion asanIL-15/sIL-15Rαcomplexistherebyfacilitated
following intracellular binding of IL-15 and this truncated
receptor isoform [8, 9]. Another form of sIL-15Rα arises by
proteolytic cleavage of mbIL-15Rα (which can be complexed
to IL-15) by the matrix metalloproteinase TNF-α converting
enzyme (TACE) [72]. Release of this form of circulating
IL-15/sIL-15Rα complex is dependent upon TACE activity,
whichinturniscorrelatedwithobesityandinsulinresistance
in mice and humans [73, 74].
Uncomplexed IL-15 and the two types of IL-15/sIL-
15Rα complexes appear to be in a dynamic equilibrium in
the circulation, and the two soluble receptor variants can
compete for binding of IL-15 [9]. However, while both forms
facilitate IL-15 secretion and can increase IL-15 half-life in
the circulation, the two variants have diﬀerential eﬀects on
IL-15 bioactivity; additionally, the two types of IL-15/sIL-
15Rα complexes can diﬀerentially bind heterodimeric versus
heterotrimeric IL-15 receptors [8, 9]. Therefore, regulation
of the various forms of sIL15Rα may be an important
element modulating IL-15 secretion and bioactivity.
In this regard, human genetic studies by three separate
laboratories have identiﬁed several single-nucleotide poly-
morphisms (SNPs) in IL15RA which impact muscularity,
fat deposition, and markers of the metabolic syndrome
[13, 14, 19]. For example, a SNP (rs2228059) in exon 3
correlates with serum triglyceride levels in males [11]. An A
to G variation in the exon 5/intron border (SNP accession6 Journal of Obesity
rs3136618) is associated with the so-called normal weight
obese/De Lorenzo syndrome, characterizing young women
with normal BMIs but greater than 30% body fat and the
presence of several markers of metabolic syndrome [12]. In a
separatestudyofmalesubjectsbyadiﬀerentgroup,thissame
SNP correlated with muscularity [10]. This SNP is close to
the site of mbIL-15Rα cleavage by TACE [72]. Whether IL-
15 is diﬀerentially complexed with sIL-15Rα variants during
obesity has not been studied, but the existence of multiple
SNPs in IL15RA which correlate with body composition
suggest this is a fertile area for future investigation.
6. Effects of IL-15 viathe Central Nervous
System(CNS)
IL-15 and IL-15 receptor subunits are expressed in several
regions of the CNS [68, 75, 76]. IL-15 has been reported
to modulate non-REM sleep [75] and to play a protective
role in neuroinﬂammation [76]. Recently, IL15RαKO mice
were reported to be hyperphagic and hyperactive, with the
suggestion that IL-15 may control hypothalamic pathways
which regulate energy balance [68]. This area is out of
the scope of the present review. However, IL-15 expression,
traﬃcking and eﬀects in the CNS are an additional, relatively
unexplored area of investigation which could impact the
balance of energy expenditure and energy intake.
7. Conclusions
Findings from cell culture, laboratory animal, and human
studiesindicateIL-15regulatesadiposetissuedepositionbya
direct mechanism. There are conﬂicting reports concerning
the tissue origin of circulating IL-15 and whether it can act
as a circulating, muscle-derived “myokine”. Whatever the
tissue of origin, recent evidence supports the hypothesis that
circulating IL-15 levels and IL-15 bioactivity are determined
by diﬀerential association of IL-15 with sIL-15Rα variants.
The concordance of basic science ﬁndings and human
geneticstudiessuggeststhesIL-15Rα,whichinturnregulates
IL-15, is an important factor inﬂuencing body composition
and insulin sensitivity. The mechanism of IL-15 action on
adipose tissue is unknown. Therefore, further investigation
into the complex IL-15/IL-15Rα axis is needed to determine
if this system can be exploited for regulation of adiposity.
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